Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects

Authors: Camila C Leança, Valéria S Nunes, Natália B Panzoldo, Vanessa S Zago, Eliane S Parra, Patrícia M Cazita, Matti Jauhiainen, Marisa Passarelli, Edna R Nakandakare, Eliana C de Faria, Eder CR Quintão

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

We have searched if plasma high density lipoprotein-cholesterol (HDL-C) concentration interferes simultaneously with whole-body cholesterol metabolism and insulin sensitivity in normal weight healthy adult subjects.

Methods

We have measured the activities of several plasma components that are critically influenced by insulin and that control lipoprotein metabolism in subjects with low and high HDL-C concentrations. These parameters included cholesteryl ester transfer protein (CETP), phospholipid transfer protein (PLTP), lecithin cholesterol acyl transferase (LCAT), post-heparin lipoprotein lipase (LPL), hepatic lipase (HL), pre-beta-1HDL, and plasma sterol markers of cholesterol synthesis and intestinal absorption.

Results

In the high-HDL-C group, we found lower plasma concentrations of triglycerides, alanine aminotransferase, insulin, HOMA-IR index, activities of LCAT and HL compared with the low HDL-C group; additionally, we found higher activity of LPL and pre-beta-1HDL concentration in the high-HDL-C group. There were no differences in the plasma CETP and PLTP activities.

Conclusions

These findings indicate that in healthy hyperalphalipoproteinemia subjects, several parameters that control the metabolism of plasma cholesterol and lipoproteins are related to a higher degree of insulin sensitivity.
Literature
1.
Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006, 58: 342-374. 10.1124/pr.58.3.1.CrossRefPubMed
2.
Leança CC, Nunes VS, Nakandakare ER, de Faria EC, Quintao EC: Does plasma HDL-C concentration interact with whole-body cholesterol metabolism?. Nutr Metab Cardiovasc Dis. 2013, 23: 279-284. 10.1016/j.numecd.2012.12.003.CrossRefPubMed
3.
von Eckardstein A, Sibler RA: Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol. 2011, 22: 26-32. 10.1097/MOL.0b013e3283412279.CrossRefPubMed
4.
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011, 364: 127-135. 10.1056/NEJMoa1001689.PubMedCentralCrossRefPubMed
5.
Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA: Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010, 30: 1642-1648. 10.1161/ATVBAHA.110.207373.CrossRefPubMed
6.
Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Sandoval JC, Ohama T, Nakagawa-Toyama Y, Matsuura F, Nishida M, Ishigami M, Hirano K, Sakane N, Kumon Y, Suehiro T, Nakamura T, Shimomura I, Yamashita S: Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb. 2009, 16: 292-296. 10.5551/jat.E599.CrossRefPubMed
7.
Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kastelein JJ, Hayden MR, Stroes ES: Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care. 2010, 33: 869-874. 10.2337/dc09-1562.PubMedCentralCrossRefPubMed
8.
Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, Villalobos-Comparan M, Rodríguez-Cruz M, Miliar-García A, Huertas-Vazquez A, Menjivar M, Romero-Hidalgo S, Wacher NH, Tusie-Luna MT, Cruz M, Aguilar-Salinas CA, Canizales-Quinteros S: Metabolic study group: association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes. 2008, 57: 509-513.CrossRefPubMed
9.
Saleheen D, Nazir A, Khanum S, Haider SR, Frossard PM: R1615P: a novel mutation in ABCA1 associated with low levels of HDL and type II diabetes mellitus. Int J Cardiol. 2006, 110: 259-260. 10.1016/j.ijcard.2005.06.059.CrossRefPubMed
10.
Daimon M, Kido T, Baba M, Oizumi T, Jimbu Y, Kameda W, Yamaguchi H, Ohnuma H, Tominaga M, Muramatsu M, Kato T: Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population. Biochem Biophys Res Commun. 2005, 329: 205-210. 10.1016/j.bbrc.2005.01.119.CrossRefPubMed
11.
Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR: β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007, 13: 340-347. 10.1038/nm1546.CrossRefPubMed
12.
Welch CL, Bretschger S, Latib N, Bezouevski M, Guo Y, Pleskac N, Liang CP, Barlow C, Dansky H, Breslow JL, Tall AR: Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the Ldlr knockout mouse model. Proc Natl Acad Sci U S A. 2001, 98: 7946-7956. 10.1073/pnas.141239098.PubMedCentralCrossRefPubMed
13.
Brunham LR, Kruit JK, Verchere CB, Hayden MR: Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest. 2008, 118: 403-408. 10.1172/JCI33296.PubMedCentralCrossRefPubMed
14.
Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA: High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009, 119: 2103-2111. 10.1161/CIRCULATIONAHA.108.843219.CrossRefPubMed
15.
Ståhlman M, Fagerberg B, Adiels M, Ekroos K, Chapman JM, Kontush A, Borén J: Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles. Biochim Biophys Acta. 2013, 1831: 1609-1617. 10.1016/j.bbalip.2013.07.009.CrossRefPubMed
16.
Coniglio RI, Meroño T, Montiel H, Malaspina MM, Salgueiro AM, Otero JC, Ferraris R, Schreier L, Brites F, Gómez Rosso L: HOMA-IR and non-HDL-C as predictors of high cholesteryl ester transfer protein activity in patients at risk for type 2 diabetes. Clin Biochem. 2012, 45: 566-570. 10.1016/j.clinbiochem.2012.02.005.CrossRefPubMed
17.
Boronat M, Saavedra P, Pérez-Martín N, López-Madrazo MJ, Rodríguez-Pérez C, Nóvoa FJ: High levels of lipoprotein (a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovasc Diabetol. 2012, 11: 81-10.1186/1475-2840-11-81.PubMedCentralCrossRefPubMed
18.
de Vries R, Kappelle PJ, Dallinga-Thie GM, Dullaart RP: Plasma phospholipid transfer protein activity is independently determined by obesity and insulin resistance in non-diabetic subjects. Atherosclerosis. 2011, 217: 253-259. 10.1016/j.atherosclerosis.2011.03.021.CrossRefPubMed
19.
Assman G, Cullen P, Kannenberg F, Schulte H: Relationship between phytosterol levels and components of the metabolic syndrome in the PROCAM study. Eur J Cardiovasc Prev Rehabil. 2007, 14: 208-214. 10.1097/HJR.0b013e3280148201.CrossRef
20.
Paramsothy P, Knopp RH, Kahn SE, Retzlaff BM, Fish B, Ma L, Ostlund RE: Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity. Am J Clin Nutr. 2011, 94: 1182-1188. 10.3945/ajcn.110.006668.PubMedCentralCrossRefPubMed
21.
Simonen PP, Gylling HK, Miettinen TA: Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care. 2002, 25: 1511-1521. 10.2337/diacare.25.9.1511.CrossRefPubMed
22.
Nunes VS, Leança CC, Panzoldo NB, Parra E, Cazita PM, Nakandakare ER, de Faria EC, Quintão EC: HDL-C concentration is related to markers of absorption and of cholesterol synthesis: Study in subjects with low vs. high HDL-C. Clin Chim Acta. 2011, 412: 176-180. 10.1016/j.cca.2010.09.039.CrossRefPubMed
23.
Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A, Arca M, Ehnholm C, Jauhiainen M: Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol. 2013, 33: 1706-1713. 10.1161/ATVBAHA.113.301397.CrossRefPubMed
24.
Huang Y, Li X, Wang M, Ning HAL, Li Y, Sun C: Lipoprotein lipase links vitamin D, insulin resistance, and type 2 diabetes: a cross-sectional epidemiological study. Cardiovasc Diabetol. 2013, 12: 17-10.1186/1475-2840-12-17.PubMedCentralCrossRefPubMed
25.
Duvillard L, Florentin E, Pont F, Petit JM, Baillot-Rudoni S, Penfornis A, Vergès B: Chronic hyperinsulinemia does not increase the production rate of high-density lipoprotein apolipoprotein AI: evidence from a kinetic study in patients with insulinoma. Arterioscler Thromb Vasc Biol. 2013, 33: 2460-2465. 10.1161/ATVBAHA.113.301597.CrossRefPubMed
26.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed
27.
Miettinen TA: Gas–liquid chromatographic determination of fecal neutral sterols using a capillary column. Clin Chim Acta. 1982, 124: 245-248. 10.1016/0009-8981(82)90393-X.CrossRefPubMed
28.
Dobiasova M, Stribrna J, Pritchard PH, Frohlich JJ: Cholesterol esterification rate in plasma depleted of very low and low density lipoproteins is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle-aged and septuagenarian men. J Lipid Res. 1992, 33: 1411-1418.PubMed
29.
Jauhiainen M, Ehnholm C: Determination of human plasma phospholipid transfer protein mass and activity. Methods Enzymol. 2005, 36: 97-101. 10.1016/j.ymeth.2004.11.006.CrossRef
30.
Ehnholm C, Kuusi T: Preparation, characterization, and measurement of hepatic lipase. Methods Enzymol. 1986, 129: 716-738.CrossRefPubMed
31.
Dullaart RP, Perton F, Sluiter WJ, de Vries R, van Tol A: Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab. 2008, 93: 4860-4866. 10.1210/jc.2008-1213.CrossRefPubMed
32.
Li L, Hossain MA, Sadat S, Hager L, Liu L, Tam L, Schroer S, Huogen L, Fantus IG, Connelly PW, Woo M, Ng DS: Lecithin cholesterol acyltransferase null mice are protected from diet-induced obesity and insulin resistance in a gender-specific manner through multiple pathways. J Biol Chem. 2011, 286: 17809-17820. 10.1074/jbc.M110.180893.PubMedCentralCrossRefPubMed
33.
Huttunen JK, Ehnholm C, Kekki M, Nikkilä EA: Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridaemia: correlations to sex, age and various parameters of triglyceride metabolism. Clin Sci Mol Med. 1976, 50: 249-260.PubMed
34.
Povel CM, Boer JM, Feskens EJ: Shared genetic variance between the features of the metabolic syndrome: Heritability studies. Mol Genet Metab. 2011, 104: 666-689. 10.1016/j.ymgme.2011.08.035.CrossRefPubMed
35.
Eriksson JW, Burén J, Svensson M, Olivecrona T, Olivecrona G: Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis. 2003, 166: 359-367. 10.1016/S0021-9150(02)00366-0.CrossRefPubMed
36.
Salah A, Khan M, Esmail N, Habibullah S, Al Lahham Y: Genetic polymorphism of S447X lipoprotein lipase (LPL) and the susceptibility to hypertension. J Crit Care. 2009, 24: e11-e14. 10.1016/j.jcrc.2009.06.005.CrossRefPubMed
37.
Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Feskens EJ, Jansen EH, Schalkwijk CG, Stehouwer C: The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). Metabolism. 2011, 60: 969-975. 10.1016/j.metabol.2010.09.006.CrossRefPubMed
38.
Quintão EC, Cazita PM: Lipid transfer proteins: past, present and perspectives. Atherosclerosis. 2010, 209: 1-9. 10.1016/j.atherosclerosis.2009.08.002.CrossRefPubMed
39.
Calabresi L, Baldassarre D, Simonelli S, Gomaraschi M, Amato M, Castelnuovo S, Frigerio B, Ravani A, Sansaro D, Kauhanen J, Rauramaa R, de Faire U, Hamsten A, Smit AJ, Mannarino E, Humphries SE, Giral P, Veglia F, Sirtori CR, Franceschini G, Tremoli E: Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. J Lipid Res. 2011, 52: 1569-1574. 10.1194/jlr.P014977.PubMedCentralCrossRefPubMed
40.
Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT: High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010, 56: 1128-1137. 10.1373/clinchem.2009.139931.CrossRefPubMed
41.
Riemens SC, van Tol A, Scheek LM, Dullaart RP: Plasma cholesteryl ester transfer and hepatic lipase activity are related to high-density lipoprotein cholesterol in association with insulin resistance in type 2 diabetic and non-diabetic subjects. Scand J Clin Lab Invest. 2001, 61: 1-9.PubMed
42.
Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW, Marcovina S, Vaisar T, Heinecke JW, Lewis GF: Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res. 2008, 103: 159-166. 10.1161/CIRCRESAHA.108.178756.CrossRefPubMed
43.
de Vries R, Borggreve SE, Dullaart RP: Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab. 2003, 49: 601-613.PubMed
44.
Rashid S, Watanabe T, Sakaue T, Lewis GF: Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003, 36: 421-429. 10.1016/S0009-9120(03)00078-X.CrossRefPubMed
45.
Weingärtner O, Lütjohann D, Vanmierlo T, Müller S, Günther L, Herrmann W, Böhm M, Laufs U, Herrmann M: Markers of enhanced cholesterol absorption are a strong predictor for cardiovascular diseases in patients without diabetes mellitus. Chem Phys Lipids. 2011, 164: 451-456. 10.1016/j.chemphyslip.2011.03.008.CrossRefPubMed
46.
Knopp RH, Retzlaff B, Fish B, Walden C, Wallick S, Anderson M, Aikawa K, Kahn SE: Effects of insulin resistance and obesity on lipoproteins and sensitivity to egg feeding. Arterioscler Thromb Vasc Biol. 2003, 23: 1437-1443. 10.1161/01.ATV.0000082461.77557.C7.CrossRefPubMed
47.
Praveen EP, Kulshreshtha B, Khurana ML, Sahoo J, Gupta N, Kumar G, Ammini A, Knadgawat R: Low HDL-cholesterol among normal weight, normoglycemic offspring of individuals with type 2 diabetes mellitus. Hormones (Athens). 2011, 10: 57-66.CrossRef
Metadata
Title
Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects
Authors
Camila C Leança
Valéria S Nunes
Natália B Panzoldo
Vanessa S Zago
Eliane S Parra
Patrícia M Cazita
Matti Jauhiainen
Marisa Passarelli
Edna R Nakandakare
Eliana C de Faria
Eder CR Quintão
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-173

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue

Original investigation

Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus

Original investigation

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner

Original investigation

Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women

Original investigation

Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study

Original investigation

Association of increased serum glycated albumin levels with low coronary collateralization in type 2 diabetic patients with stable angina and chronic total occlusion

Original investigation

Changes in red blood cell membrane structure in type 2 diabetes: a scanning electron and atomic force microscopy study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits